Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm)

by A. Medaglia, A.K. Nooka, M.V.M. Manteca, N. Bahlis, K. Weisel, A. Oriol, A.A. Alonso, A. Suvannasankha, B. Holkova, K. Luptakova, D. Fecteau, B.E. Kremer, M. Nichols, D. Williams, D.A Smith, R.C. Jewell, R. Montes de Oca, J. Opalinska, S. Trudel
Published 2020-09-01